Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Active:	Yes
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer	NCT ID:	NCT06619236
Trial Phases:	Phase III	Protocol IDs:	GCT1184-02 (primary) NCI-2024-09116 2024-514822-21 ENGOT-OV86 GOG-3107 jRCT2031250064 PRO1184-002 RAINFOL-OV2
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genmab
NCI Full Details:	http://clinicaltrials.gov/show/NCT06619236

Summary

This phase 3 study will be conducted in different countries all over the world.

The purpose of this study is to compare how well Rina-S works against platinum-resistant
ovarian cancer compared to chemotherapy drugs that are already approved and used for
platinum-resistant ovarian cancer.

Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy
agents that are considered standard medical care. There is an equal (50:50) chance of
getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will
know what treatment they are assigned to until the first dose.

All participants will receive active drug; no one will be given placebo.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.